Log in
Enquire now
‌

US Patent 10183024 Crystalline forms of ibrutinib

Patent 10183024 was granted and assigned to Apotex on January, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Apotex
Apotex
Current Assignee
Apotex
Apotex
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10183024
Patent Inventor Names
Fabio E. S. Souza0
Annyt Bhattacharyya0
Bahareh Khalili0
Boris Gorin0
Allan W. Rey0
Date of Patent
January 22, 2019
Patent Application Number
15827471
Date Filed
November 30, 2017
Patent Primary Examiner
‌
Jeffrey H Murray
Patent abstract

The present invention provides crystalline forms of Ibrutinib. Specific crystalline forms provided by the present invention include Ibrutinib Form APO-I, an anhydrous form; APO-II, a methyl benzoate solvate of Ibrutinib; and APO-IV, a methyl salicylate solvate of Ibrutinib.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10183024 Crystalline forms of ibrutinib

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.